Drug development

Genomics has the potential to significantly improve the efficacy of drugs and develop targeted therapies.

Merck Join The SGC With C$7.5M Contribution

Merck join the SGC with multi-million dollar contribution. Merck have announced a contribution of C$7.5 million to the Structural Genomics Consortium (SGC), joining as a member organisation. The supported project focus on per-competitive research to develop small inhibitory molecules called chemical probes to study epigenetic mechanisms of regulation. In collaboration with leading clinical institutions in […]

CRISPR For Genome Editing

CRISPR, a pioneering genome-editing technique, technology will allow AstraZeneca to identify and validate new drug targets in preclinical models that closely resemble human disease.

Curing The Un-Curable

Michael Vellard is a specialist in developing therapies for difficult to treat rare genetic diseases. Read the story behind his remarkable success.